These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26448313)

  • 21. Pivotal role of injection volume on sunken cheek prevention in masseter muscle BoNT-A injection: A cadaver study.
    Yu P; Zhai H; Li Z; Dong R; Wu T; Li Y; Di Z; Sun Y; Long X; Yu N
    J Cosmet Dermatol; 2022 Jan; 21(1):137-141. PubMed ID: 34897934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of botulinum toxin type A for the treatment of masseteric muscle hypertrophy.
    Arikan OK; Tan FU; Kendi T; Koc C
    J Otolaryngol; 2006 Feb; 35(1):40-3. PubMed ID: 16527016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring botulinum toxin's impact on masseter hypertrophy: a randomized, triple-blinded clinical trial.
    de Souza Nobre BB; Rezende L; Barbosa Câmara-Souza M; Sanchez-Ayala A; Blass R; Carbone AC; Manso AC; Ernberg M; Christidis N; De la Torre Canales G
    Sci Rep; 2024 Jun; 14(1):14522. PubMed ID: 38914688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases.
    Baş B; Ozan B; Muğlali M; Celebi N
    Med Oral Patol Oral Cir Bucal; 2010 Jul; 15(4):e649-52. PubMed ID: 20173718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultrasonographic Considerations for Safe and Efficient Botulinum Neurotoxin Injection in Masseteric Hypertrophy.
    Lee HJ; Jung SJ; Kim ST; Kim HJ
    Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33406757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First case of anaphylaxis after botulinum toxin type A injection.
    Moon IJ; Chang SE; Kim SD
    Clin Exp Dermatol; 2017 Oct; 42(7):760-762. PubMed ID: 28639343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients.
    Lee SH; Wee SH; Kim HJ; Yeo UC; Lee NH; Lee SW; Cho SB
    J Dermatolog Treat; 2013 Apr; 24(2):133-6. PubMed ID: 21888570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Botulinum toxin type A in the management of masseter muscle hypertrophy.
    Castro WH; Gomez RS; Da Silva Oliveira J; Moura MD; Gomez RS
    J Oral Maxillofac Surg; 2005 Jan; 63(1):20-4. PubMed ID: 15635552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unilateral masseter muscle hypertrophy: morphofunctional analysis of the relapse after treatment with botulinum toxin.
    Peretta R; Melison M; Meneghello R; Comelli D; Guarda L; Galzignato PF; Concheri G; Ferronato G
    Cranio; 2009 Jul; 27(3):200-10. PubMed ID: 19697649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Painful unilateral temporalis muscle enlargement: reactive masticatory muscle hypertrophy.
    Katsetos CD; Bianchi MA; Jaffery F; Koutzaki S; Zarella M; Slater R
    Head Neck Pathol; 2014 Jun; 8(2):187-93. PubMed ID: 23900775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discussion on The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy.
    Hwang K
    Dermatol Surg; 2014 Dec; 40(12):1340-1. PubMed ID: 25380090
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of botulinum toxin type A in a case of persistent parotid sialocele.
    Chow TL; Kwok SP
    Hong Kong Med J; 2003 Aug; 9(4):293-4. PubMed ID: 12904619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Change of distribution and timing of bite force after botulinum toxin type A injection evaluated by a computerized occlusion analysis system.
    Song JH; Cho ES; Kim ST; Ahn HJ
    Yonsei Med J; 2014 Jul; 55(4):1123-9. PubMed ID: 24954346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxin type A injections for masticatory muscles hypertrophy: A systematic review.
    Rauso R; Lo Giudice G; Tartaro G; Zerbinati N; Nicoletti GF; Fragola R
    J Craniomaxillofac Surg; 2022 Jan; 50(1):7-18. PubMed ID: 34620536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Masseteric hypertrophy: considerations regarding treatment planning decisions and introduction of a novel surgical technique.
    Pary A; Pary K
    J Oral Maxillofac Surg; 2011 Mar; 69(3):944-9. PubMed ID: 21195532
    [No Abstract]   [Full Text] [Related]  

  • 36. Botulinum toxin injection for salivary gland enlargement evaluated using computed tomographic volumetry.
    Bae GY; Yune YM; Seo K; Hwang SI
    Dermatol Surg; 2013 Sep; 39(9):1404-7. PubMed ID: 23815364
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report.
    Mandel L; Tharakan M
    J Oral Maxillofac Surg; 1999 Aug; 57(8):1017-9. PubMed ID: 10437733
    [No Abstract]   [Full Text] [Related]  

  • 38. Botulinum toxin as an alternative for the treatment of aesthetic deformities.
    Barbosa MV; Nahas FX; Ferreira LM; Al-Ahmad HT; Al-Qudah M
    Saudi Med J; 2006 Oct; 27(10):1613; author reply 1613. PubMed ID: 17013500
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of Incobotulinum toxin-A for the treatment of masseter muscle hypertrophy in Asian Indian patients: A 2-year follow-up study.
    Shome D; Vadera S; Shiva Ram M; Kapoor R
    J Cosmet Dermatol; 2020 Aug; 19(8):1892-1899. PubMed ID: 32539203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of botulinum toxin (botox) in the management of masseter muscle hypertrophy: a simplified technique.
    Andrade NN; Deshpande GS
    Plast Reconstr Surg; 2011 Jul; 128(1):24e-26e. PubMed ID: 21701301
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.